Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Impaired Immune Regulation After Radioiodine Therapy for Graves’ Disease and the Protective Effect of Methimazole
source: Endocrine
year: 2016
authors: Côté-Bigras S, Tran V, Turcotte S, Rola-Pleszczynski M, Verreault J, Rottembourg D
summary/abstract:Both therapies for Graves’ disease (GD), radioactive iodine (RAI) and antithyroid drugs (ATD), were reported to have specific immune effects. We aimed at investigating the effects of RAI therapy on cellular subsets involved in immune regulation.
We conducted a thirty day follow-up prospective cohort study of adult patients. Patients eligible for RAI therapy at our centre were approached. Twenty seven patients with GD were recruited, among whom 11 were treated with ATD. Twenty-two healthy subjects (HS) were also studied. Over time, frequency of regulatory T cells (Treg) and of invariant natural killer T cells (iNKT), along with Treg cell-mediated suppression and underlying mechanisms, were monitored in the peripheral blood. Variance in frequency of Treg and iNKT after RAI therapy was higher in GD patients than in HS over time (p < 0.0001). Reduced Treg suppressive function was observed after RAI therapy in GD patients (p = 0.002). ATD medication prior to RAI dampened these outcomes: less variation of Treg frequency (p = 0.0394), a trend toward less impaired Treg function, and prevention of reduced levels of suppressive cytokines (p < 0.05).
Shortly after RAI therapy, alterations in immunoregulatory cells in patients with GD were observed and partially prevented by an ATD pretreatment. Worsening of autoimmunity after RAI was explained in previous studies by enhanced immune activity. This study adds new highlights on immune regulation deficiencies after therapeutic interventions in thyroid autoimmunity.
organization: Sherbrooke University Hospital and Faculty of Medicine, CanadaDOI: 10.1007/s12020-015-0832-2
read more
Related Content
-
Clinical and Socioeconomic Factors Influence Treatment Decisions in Graves’ DiseaseBackground: Definitive treatment of Gra...
-
Radioiodine-Associated Exacerbation of Graves’ Orbitopathy in the Japanese Population: Randomized Prospective ...Context: Exacerbation of Graves' orbito...
-
FDA Drug Safety Communication: New Boxed Warning on Severe Liver Injury With PropylthiouracilThe United States Food and Drug Administ...
-
Graves’ Disease Treatment for Someone in Their 20sHyperthyroidism triggered by Graves’ d...
-
The Second Antithyroid Drug Treatment is Effective in Relapsed Graves’ Disease Patients: A Median 11-Year Foll...Background: Antithyroid drug (ATD) is a...
-
Management of Thyroid Eye Disease in the United Kingdom: A Multi-Centre Thyroid Eye Disease AuditThis article aims to provide baseline da...
-
Radioactive Iodine Therapy vs. Antithyroid Medications for Graves’ DiseaseGraves disease is the most common cause ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.